Pfizer Vaccine Granted Priority Review for Full U.S. Approval

Pfizer Inc. said its Covid-19 vaccine was granted priority review by U.S. regulators, putting it on track for a potential full approval by early next year.

The drugmaker and its German partner BioNTech SE said in a statement Friday that the Food and Drug Administration plans to decide whether to approve the shot for use in people 16 and older by January 2022.